

# Delivering rapid and accurate results when it matters most

The turnaround time for test results listed below is a general guideline for the testing methodologies at NeoGenomics. TATs vary by test/panel and level of service.\*



## Cytogenetics

### Standard

6 days

### Known or suspected plasma cell neoplasm

8 days



## Flow cytometry

### Standard

1 day

### MRD panels

1-2 days



## Fluorescence in situ hybridization (FISH)

### Non-NeoTYPE® cases

3-5 days

### NeoTYPE® cases

7 days



## Immunohistochemistry (IHC)

1-2 days



## In situ hybridization (ISH)

2-5 days



## Molecular (non-NGS)

5-10 days



## Next-generation sequencing (NGS)

### Neo PanTracer™ portfolio

8-10 days for tissue testing, and within 7 days for PanTracer LBx

### Neo Comprehensive® hematologic disease profiles

8-11 days

### NeoTYPE® profiles

8-14 days

### RaDaR® ST MRD

First timepoint: 28-35 days

Follow-up timepoints: 7-10 days

### Fusion-only panels

21 days



## Other services

### Consultation, including morphology

2-5 days

For more information, please contact your NeoGenomics representative, call our Client Services team at 866.776.5907, option 3, or visit our test menu at [NeoGenomics.com/test-menu](https://www.NeoGenomics.com/test-menu).

FISH = Fluorescence in situ hybridization; IHC = Immunohistochemistry; ISH = In situ hybridization; MRD = Minimal or Molecular Residual Disease; NGS = Next-generation sequencing; TAT = Turnaround time

\* TATs stated are from the time of receipt of specimen to reporting. The TATs listed here are for planning purposes only. Our website lists the most up-to-date turnaround times for each of our tests. Actual turnaround times may vary due to sample quality, volume, assay complexity, and operational considerations. While we strive to meet or exceed published turnaround times, they are not guaranteed.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.